Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796230 | 0.90 | KDM4E (0.41) | MEN1KMT2AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL4776885 | 0.88 | PIK3CA (0.52) | MEN1KMT2AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL4792096 | 0.80 | PIP4K2A (0.47) | MEN1KMT2AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL3937437 | 0.77 | CYP3A4 (0.38) | CYP1A2CYP3A4SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4776483 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL3925104 | 0.76 | KCNK3 (0.41) | MEN1KMT2ACYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL3937931 | 0.75 | LMNA (0.49) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL3930613 | 0.71 | PIK3CA (0.67) | KDM4EPIK3CAATMMAPK13ALDH1A1 | |
| SCHEMBL1791657 | 0.70 | PIK3CA (0.68) | KDM4EBRAFPIK3CAALDH1A1MAPT | |
| SCHEMBL4795493 | 0.70 | PIP4K2A (0.48) | MEN1KMT2AKDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | MEN1 1354/4885KMT2A 3984/4885KDM4E 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.